乌苯美司胶囊联合SOX化疗对晚期胃癌患者的临床疗效研究

Clinical Effect of Ubenimex Capsules Combined with SOX Chemotherapy on Treatment of Advanced Gastric Cancer

目的:探讨乌苯美司胶囊联合SOX化疗对晚期胃癌患者的临床疗效及安全性。方法:选择2013年9月至2015年9月我院接诊的90例晚期胃癌患者,通过随机数表法分为观察组(n=45)和对照组(n=45)。对照组给予SOX化疗方案,观察组在此基础上联合乌苯美司胶囊。比较两组治疗前后CD_4^+、CD_8^+、CD_4^+/CD_8^+、血清基质金属蛋白酶(MMP)-2、MMP-9水平、临床疗效、不良反应发生情况以及6个月、12个月生存率。结果:治疗后,观察组CD_4+、CD_4^+/CD_8^+显著高于对照组(P<0.05),血清MMP2、MMP-9水平明显低于对照组(P<0.05);临床疗效总有效率高于对照组[68.89%(31/45)vs48.89%(22/45)](P<0.05),血小板下降、白细胞下降、恶心呕吐、肝功异常的发生率均显著低于对照组(P<0.05)。观察组在6个月、12个月时生存率均高于对照组[93.33%(42/45)vs77.78%(35/45),82.22%(37/45)vs57.78%(26/45)](P<0.05)。结论:与单用SOX方案相比,乌苯美司胶囊联合SOX化疗方案治疗晚期胃癌患者的效果显著,可有效改善免疫功能,提高远期生存率,且安全性更高。

Objective： To study the clinical effect and safety of ubenimex capsules and SOX chemotherapy on the advanced gastric cancer. Methods： 90 patients with advanced gastric cancer who were treated in our hospital from September 2013 to September 2015 were selected and randomly divided into the observation group （n=45） and the control group （n=45）. The patients in the control group were treated with SOX chemotherapy, while the patients in the observation group were treated with ubenimex capsules on the basis of control group. Then the serum levels of MMP-2 and MMP-9, the immune functions, the clinical efficacy, the adverse reactions and survival rate of two groups were observed and compared before and after the treatment. Results： After treatment, the CD4＋, CD4＋/CD8＋ in the observation group were higher than those of the control group （P〈0.05）; The levels of MMP2 and MMP-9 in the observation group were lower than those of the control group （P〈0.05）; The total effective rate of the observation group was higher than that of the control group [68.89%（31/45） vs 48.89%（22/45）] （P〈0.05）; The incidence of thrombocytopenia, leukopenia, nausea and vomiting and abnormal liver functions in the observation group was lower than that of the control group （P〈0.05）; The survival rate of the observation group was higher than that of the control group at 6 months and 12 months [93.33% （42/45） vs 77.78% （35/45）, 82.22% （37/45） vs 57.78% （26/45）]（P〈0. 05）. Conclusion： Compared with SOX chemotherapy alone, ubenimex capsules and SOX chemotherapy could effectively improve the immune function, enhance the long-term survival rate with high safety of patients with advanced gastric cancer.